Platform
How the discovery work is done
The target, the workflow, and where the lead programme has got to.
The target
VP40 drives assembly of new viral particles and their release from an infected cell — a step the virus cannot skip. It is also highly conserved across filoviruses, so a candidate that binds it keeps working as strains drift.
Model from PDB 3TCQ. Not a structure of our own.
SUDV VP40 matrix protein · PDB 3TCQ
Conserved where it counts
Sequence identity across filovirus VP40, by region. The binding site sits in the conserved core.
Representative peptide fold · PDB 2MLT
Design antiviral peptides at computational scale and speed
- De novo binder design against a defined epitope
- Sequence ranking by predicted binding affinity
- Iterative refinement of top-scoring candidates
- Developability and stability screening
What is and is not published
The peer-reviewed article below covers the computational identification of the lead candidates. Sequences, structures, scoring methodology and assay results are unpublished know-how, shared with collaborators under agreement. Sequences and figures shown elsewhere on this site are illustrative and are not candidate data.
Publications
Scientific Foundations
Our platform is built on published, peer-reviewed science. Everything we claim about our discovery workflow traces back to work that has been through review.
- Peer-reviewed article2025
In Silico Identification of Antiviral Peptides as Potential Leads Against Sudan Ebolavirus VP-40
Omara, B. et al.
Peer-reviewed work underpinning our lead program: computational identification and prioritization of antiviral peptide leads against the Sudan ebolavirus VP40 matrix protein.
Full text available on request — get in touch.
Contact
Let's Build the Next Generation of Antivirals
Whether you are a researcher, funding organisation, biotechnology company or global health partner, we would love to explore collaboration.